Extensive research has focused on the function of glucose metabolism in immune cell maturation and differentiation, energy production, storage, and regulation. CD4⁺ T cells can be subdivided into several subpopulations, including Th1, Th2, Th9, Th17, Th22, and regulatory T (Treg) cells. Studies have confirmed the essential role of glucose in T cell activation and differentiation, demonstrating that upregulation of glycolytic flux is required for Th1, Th2, and Th17 differentiation (Wik and Skalhegg, 2022). However, the function of the glucose analog D-mannose in the immune response of T cells remains unknown. The role of D-mannose in T cell differentiation in a mouse model of diabetes and airway inflammation was first reported by Zhang et al. (2017). CFSE staining of mouse naive T cells stimulated with CD3/CD28 and mannose for 48–72 h demonstrated that mannose inhibited T cell proliferation. The mRNA expression levels of the cytokines Ifng, Il2, Il4, and Il10 associated with Th1 and Th2 decreased, whereas the levels of Foxp3 mRNA increased significantly. This finding suggests that mannose stimulates the development of Treg cells. D-mannose supplementation in drinking water suppressed immunopathological signs in mice with autoimmune diabetes and airway inflammation models and increased the proportion of Foxp3⁺ Treg cells in mice, as determined through in vivo experiments.

TGF-β signaling serves a crucial role in the production of Treg cells. Mannose-induced Treg cells exhibited similar inhibitory activity to TGF-β-induced Treg cells and inhibited the proliferation of naive T cells (Chen et al., 2003; Chen and Konkel, 2015; Zhang et al., 2017). The addition of mannose promoted TGF-β signaling in T cells, where the mRNA levels of Smad7 and Fos were increased markedly. An antibody that neutralizes TGF-β prevented TGF-β signaling and inhibited the mannose-induced increase in Foxp3 gene expression and Treg cells. For naive T cells in Smad3-deficient mice, mannose stimulation significantly decreased Treg cells, suggesting that TGF-β plays an essential function in the mannose-induced production of Treg cells.

Studies have reported that integrin α_vβ₈ and reactive oxygen species (ROS) are implicated in the TGF-β-induced activation of immune cells (Amarnath et al., 2007; Worthington et al., 2015). Similarly, the mRNA expression levels of Itgav and Itgb8 were significantly elevated in mannose-stimulated naive T cells. The deletion of integrin α_vβ₈ significantly decreased the mannose-induced production of Treg cells. Mannose stimulation increased ROS production in T cells, and after inhibiting ROS activity, the number of mannose-induced Treg cells decreased significantly. In integrin α_vβ₈-deficient naive T cells stimulated with mannose and supplemented with NAC to neutralize ROS activity, Treg cells were decreased by 70%–80%. This finding indicates that integrin α_vβ₈ and ROS play independent and complementary functions in mannose-mediated TGF-β activation and Treg production. Furthermore, the efficient utilization of fatty acid oxidation by mannose-stimulated T cells may account for the high level of ROS production. The unrecognized immunomodulatory function of D-mannose may have clinical applications in immunopathology and should be promising for treating inflammatory responses.

The balance of Th1 and Th2 cell differentiation plays an important regulatory and paracrine role in the body’s immune response against pathogens. Excessive Th1 cell activation and IFN-γ production is associated with the development of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and certain hypersensitivity diseases (Rogers and Croft, 1999). Glycolysis stimulates the proliferation of Th1 cells and the production of the cytokine IFN-γ in Th1 cells (Shi et al., 2011; Chang et al., 2013). By inhibiting hexokinase activity, 2DG—a competitive inhibitor of phosphoglucose isomerase—inhibits the metabolic flux of glycolysis. Through PMI, glycolysis establishes a vital link to mannose metabolism; therefore, it was hypothesized that mannose metabolism might also be involved in Th1 cell differentiation. Zygmunt et al. (2018) confirmed this hypothesis (Zygmunt et al., 2018).

Adding exogenous mannose to a glucose-containing medium could promote cell proliferation and compensate for the decreased IFN-γ in Th1 cells caused by 2DG and galactose. However, neither the inhibitory effect on cell motility caused by a reduction in glycolytic metabolism nor lactate production was affected. In terms of promoting IFN-γ cell production, the addition of mannose alone to the Th1 differentiation medium had the same effect as the addition of glucose alone. The balance of hexose metabolism is required for expression in Th1 cells, and the concentration of hexose in the medium regulates the expression of IFN-γ and the proliferation of Th1 cells. Compared with 10 or 25 mM glucose culture conditions, IFN-γ expression was inhibited in 1 mM glucose culture conditions. Low concentrations of mannose (1 mM) promote IFN-γ expression and Th1 cell proliferation, whereas high concentrations (25 mM) exhibited the opposite effect. When glycolysis was inhibited by the addition of 2DG to Th1 cell cultures, the phosphorylation of T-bet, STAT1, and STAT4 governed the promotion of IFN-γ secretion by supplemental mannose in Th1 cells. When glycolysis was inhibited, phosphorylation of T-bet and STAT1, STAT4 in Th1 cells exhibited low expression levels, and mannose supplementation increased their expression, indicating that mannose regulates Th1 cell differentiation at the transcriptional level (Zygmunt et al., 2018).

Macrophages are the first line of defense in intrinsic immunity; they are present throughout the body, respond to different pathogen signals resulting in varying activation states, and play a crucial role in the development and progression of inflammation. Their functional plasticity is contingent on the modification of metabolic processes. Macrophage activation increases glucose and glutamine uptake rates, lactate production rates, and glycolytic levels, thereby promoting the LPS-induced production of the inflammatory cytokine IL-1β. Glycolysis swiftly generates adenosine triphosphate (ATP) and biosynthetic intermediates to support the effector functions of macrophages, including glucose that can enter the pentose phosphate pathway and promote the maintenance of an inflammatory state (Pearce and Pearce, 2013; O’Neill et al., 2016).

Through in vitro experiments, Torretta et al. (2020) demonstrated that mannose could dose-dependently inhibit LPS-induced IL-1β production in mouse bone marrow-derived macrophages (BMDMs), thereby inhibiting macrophage activation (Torretta et al., 2020). The mannose receptor (MR)—a C-type lectin receptor expressed on phagocytes—binds mannose residues on pathogenic microorganisms and regulates inflammatory responses (Taylor et al., 2005). Exogenous mannose can enter the cell via GLUT to regulate glucose metabolism and bind to MR on the cell surface to influence cell function. By contrast, silencing MR expression in macrophages derived from mouse bone marrow did not affect the expression level of IL-1β inhibited by mannose, indicating that mannose inhibits IL-1β production in macrophages primarily via a pathway independent of MR. Intriguingly, the inhibitory effect of mannose on macrophage IL-1β was higher in low glucose (5.5 mM) culture conditions than in high grape content culture conditions, indicating that the effect of mannose on macrophage IL-1β secretion could be because of interference with the glucose metabolic pathway in cells. This hypothesis was confirmed through experiments, such as liquid chromatography-mass spectrometry analysis. In LPS-induced macrophages, the addition of mannose inhibited the rate of glucose consumption and lactate secretion and decreased the level of glucose-6-phosphate, an intermediate product of glucose metabolism. Furthermore, M-6-P levels increased within the cells. Inflammatory macrophages utilize less glucose in glycolysis after adding mannose; consequently, less carbon enters the TCA cycle, and the concentration of its intermediate product succinate decreases. This modification inhibits succinate-mediated activation of hypoxia-inducible factor 1A (HIF-1α), which sustains IL-1β production by promoting HIF-1α stabilization in pro-inflammatory macrophages (Tannahill et al., 2013). In healthy cells, PMI catalyzes the conversion of M-6-P to F-6-P, which then enters the glycolytic pathway. Overexpression of PMI in macrophages decreased the accumulation of M-6-P in LPS-induced pro-inflammatory macrophages under mannose stimulation. Increased PMI levels eliminated the effect of mannose on glucose utilization in LPS-activated BMDM and reversed the decrease in succinate and HIF-1α expression under mannose stimulation. The suppression of PMI expression and the increase in lactate content, succinate content, and IL-1β expression in LPS-stimulated macrophages treated with mannose indicates that PMI plays an essential role in the pro-inflammatory macrophage response to mannose.

The release of inflammatory mediators by activated macrophages plays a crucial role in pathogen immunity, but prolonged inflammatory stimulation is detrimental to tissue health, as seen in ulcerative colitis. In ulcerative colitis, mannose substantially mitigated the weight loss and inflammatory progression induced by dextran sodium sulfate (DSS) (Torretta et al., 2020). CD11b⁺ cells accumulated in the lamina propria of DSS-treated mice, and magnetic bead isolation of CD11b⁺ cells from the submucosa of the colon of DSS-treated mice was similar to that of inflammatory macrophages under LPS treatment in vitro, and mannose stimulation similarly attenuated their lactate and succinate levels and reduced their IL-1β level expression. The metabolic process of macrophage activation drives the safe and effective use of mannose as an anti-inflammatory agent.

In 1973, Steinman identified a unique cell type in the peripheral lymphoid organs of mice that exhibited numerous dendritic or pseudopod-like projections, leading to its designation as DCs (Steinman and Cohn, 1973). DCs are now recognized as the most potent antigen-presenting cells (APCs) and play a pivotal role in initiating and sustaining immune responses, particularly the T-cell-mediated immune response. Immature DCs in peripheral tissues capture and internalize antigens, which are then processed into MHC–peptide complexes. Subsequently, DCs migrate to secondary lymphoid organs, undergo maturation, and present the MHC-antigen peptide complexes to naive T cells, thus instigating an adaptive immune response (Banchereau and Steinman, 1998). Wang et al. (2021) investigated the role of mannose in autoimmune disease treatments and discovered that mannose’s immunomodulatory effects were tied to the induction of immature conventional dendritic cells (cDCs) and a reduction in effector T cell activation (Wang et al., 2021). The expression of surface molecules on DCs is dynamic, varying according to tissue localization and maturation status. Immature DCs predominantly express antigen-uptake-related molecules, such as CD32b and CD64, along with mannose receptors (MR, also known as CD206), which serve as endocytic receptors (Schuette et al., 2016; Cummings, 2022). Studies have indicated that mannose augmented CD206 expression on bone marrow-derived dendritic cells (BMDCs) in vitro and within chronic graft-vs.-host disease (cGVHD) and lupus-susceptible (B6/lpr) models in vivo. Moreover, CD32b and CD64 expression in mannose-treated BMDCs persisted at elevated levels after LPS stimulation, implying that mannose curtails DC maturation. In the cGVHD model, mannose administration reduced both inflammatory cytokine production and the expression of activation markers CD40 and CD80, subsequently inhibiting DC maturation. Concurrently, in a co-culture assay, D-mannose suppressed the antigen-specific proliferation and activation of CD4⁺ T cells (Wang et al., 2021).

In addition to transporting oxygen, erythrocytes—the most abundant type of cell in the blood—promote phagocytosis, eliminate immune complexes, and conduct immunomodulation. When human erythrocytes are incubated with mannose, M-6-P accumulates swiftly. PMI, not hexokinase, is the limiting enzyme for converting mannose to fructose in erythrocytes. PMI is also present in pig and rat erythrocytes. In hexokinase-deficient human cells, glucose utilization was decreased, whereas mannose utilization was elevated, and PMI activity was significantly increased. Hexokinase-deficient cells incubated with mannose accumulated M-6-P at a rate roughly a third of that of normal cells. Hexokinase-deficient cells preferentially utilize mannose over glucose more rapidly because of PMI’s regulatory effect on mannose utilization (Beutler and Teeple, 1969).

Erythrocytes can be stored under conventional conditions for up to 42 days, and the process that degrades their quality and impairs their oxygen transport function during storage is known as erythrocyte storage injury (RSL). It is possible to reduce RSL to manipulate the metabolic processes of erythrocytes and optimize the components in the erythrocyte storage solution. Erythrocytes stored at 9 or 18 mmol/L in a storage solution SAGM containing uniformly labeled 13C-fructose or 13C-mannose absorbed fructose and mannose in the presence of glucose when refrigerated. Mannose was more efficiently metabolized via glycolysis than glucose. Fructose decreased ATP levels and made a negligible contribution to ATP maintenance. By contrast, the contribution to ATP for SAGM with added mannose was essentially the same as for SAGM without added mannose. After 10 days of storage, adding fructose or mannose to erythrocyte SAGM concentrates may not counteract the alterations in erythrocyte metabolism. At high glucose concentrations, neither fructose nor mannose enhanced the ability of SAGM to maintain and protect erythrocyte mass during storage (Rolfsson et al., 2017).

In the early 20th century, Prof. Otto Warburg made the pivotal discovery that tumor cells preferentially metabolize glucose to lactic acid via glycolysis, even in the presence of ample oxygen. This phenomenon, termed the ‘Warburg effect’, spurred subsequent research into tumor metabolism (Warburg, 1956). Indeed, metabolic reprogramming is now recognized as a critical hallmark of cancer (Hanahan, 2022). In terms of the oxidative phosphorylation metabolism required to sustain cellular life processes, tumor cells are wholly distinct from normal cells. A series of metabolic alterations in tumor cells, mainly characterized by the Warburg effect, exhibit large amounts of glucose uptake, enhanced aerobic glycolytic metabolism, and production of large quantities of lactic acid, which are conducive to malignant proliferation, invasive metastasis, and adaptation to a hostile survival environment of tumors. Therefore, studies have focused on modulating glucose metabolic pathways to treat tumors (Vander Heiden et al., 2009; Koppenol et al., 2011; Pavlova and Thompson, 2016). In 2018, Kevin M. Ryan’s team at Cancer Research UK demonstrated that mannose inhibits tumor growth by interfering with cellular glucose metabolism and substantially boosts the anti-tumor effects of chemotherapy drugs (Cisplatin and Adriamycin). Only mannose significantly inhibited the growth of human osteogenic sarcoma cell lines U2OS-E1a and Saos-2 and human pancreatic cancer cell line KP-4 when treated with high concentrations (25 mM) of each of the five monosaccharides (mannose, glucose, galactose, fructose, and fucose). When mannose enters tumor cells, it accumulates intracellularly as M-6-P, which inhibits tumor cell proliferation by interfering with glucose metabolism and blocking the tumor’s energy source. This study also revealed a correlation between the level of PMI expression in tumor cells and the inhibition of tumor cell growth by mannose. Tumor cells with low levels of PMI expression or reduced function were more sensitive to mannose therapy. By contrast, mannose had no significant inhibitory effect or only a weak effect on the growth of tumor cells containing higher PMI levels by interfering with PMI expression via RNA interference, thereby rendering the cells sensitive (Gonzalez et al., 2018).

Zhong et al. (2022) obtained comparable findings that regarding the role of mannose in advanced prostate cancer (PCa). Mannose inhibits PCa cell proliferation and promotes apoptosis. The process is regulated by altered mitochondrial mechanisms. Intracellular accumulation of mannose decreased mitochondrial membrane potential, leading to decreased ATP production in PCa cells, increased ROS levels in PCa cells, and enhanced expression of the pro-apoptotic factors Bax and Bak. Mannose-treated PCa cells altered mitochondrial morphology and diminished the mitochondrial fission protein FIS1. Furthermore, low expression of PMI—a key enzyme of mannose metabolism—was associated with a poor prognosis in PCa patients, whereas downregulation of PMI expression in PCa cells increased the anticancer effect of mannose (Zhong et al., 2022). Cancer metabolism is temporally and spatially heterogeneous. The metabolic phenotype of tumor cells is not uniform across cancer types and undergoes continuous change during tumor progression (Xiao et al., 2023b). The signaling pathways used to treat tumors must vary because of the heterogeneity of cancer cells. Mannose inhibits proliferation and promotes apoptosis in glioma cells, and PMI inhibition facilitates apoptosis in glioma cells. Most processes inhibit the Wnt/β-catenin signaling pathway. Mannose inhibits the expression of 6-methylguanine DNA methyltransferase (MGMT) to increase glioma cells’ sensitivity to temozolomide (TMZ) (Fei et al., 2022). PMI depletion decreased the phosphorylation of FGFR family receptors in malignant glioma cell lines and the signaling of FRS2, Akt, and MAPK. PMI knockdown substantially decreased the clonal survival of glioma cells following ionizing radiation (Cazet et al., 2014).

Triple-negative breast carcinomatosis (TNBC)—characterized by cells lacking estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)—is the least prognostic and most aggressive molecular subtype of breast tumors, and chemotherapy and radiotherapy are less effective treatments for TNBC (Harbeck et al., 2019; Yin et al., 2020). Zhang et al. (2022) revealed a new function and mechanism for mannose in TNBC immunotherapy and radiation therapy (Zhang et al., 2022). Mannose facilitates the degradation of PD-L1 by affecting its glycosylation, thereby enhancing the efficacy of immunotherapy and radiotherapy in TNBC. PD-L1 is a classic tumor immune checkpoint molecule that inhibits the proliferation and cytotoxicity of T cells by binding to PD1 molecules on T cells, thereby facilitating tumor cell evasion of T cell surveillance (Freeman et al., 2000). Mannose inhibits PD-L1 expression by interfering with PD-L1 glycosylation. AMPK-mediated phosphorylation of the PD-L1 S195 site promotes PD-L1 ubiquitination and targets it to the proteasome. The degradation of PD-L1 by mannose promotes T-cell activation and the destruction of tumor cells by T-cells. The combination of mannose and PD-L1 blockers substantially inhibited the growth of TNBC and increased the survival rate of mice with tumors (Zhang et al., 2022). In addition, PD-L1 can bind to RNA in the cytoplasm and protect the mRNA stability of genes involved in DNA damage repair, promoting DNA damage repair in tumor cells (Tu et al., 2019). Mannose-induced PD-L1 degradation also destabilizes messenger RNA of DNA damage-repair-related genes, which sensitizes breast cancer cells to ionizing radiation therapy and promotes radiation therapy for TNBC in rodents (Zhang et al., 2022). It established a relationship between cellular metabolism and tumor immune evasion, revealed the mechanism of D-mannose targeting PD-L1 degradation, and proposed a novel clinical treatment strategy for TNBC.

Previous studies on mannose for tumor cell proliferation and metabolism have demonstrated that mannose has a beneficial effect on treating low PMI-expressing tumors. By contrast, hematological malignancies and leukemia cells express high levels of PMI. PMI enables mannose to enter the glycolytic pathway, TCA cycle, and pentose phosphate pathway (PPP) of leukemia cells, providing an energy source during glucose deprivation. Therefore, mannose in the blood can be considered an energy source for the glycolytic pathway. However, when mannose levels exceed the PMI-treated load, PMI expression is inhibited, leading to the accumulation of M-6-P caused by mannose load, which can inhibit glycolytic levels, mitochondrial metabolism, or the expression of related genes in the TCA cycle, thereby inhibiting the growth of leukemic cells, as shown in Fig. 3 (Saito et al., 2021). In acute myeloid leukemia (AML), high PMI expression is a negative prognostic factor. Meanwhile, AML cells increased expression of genes related to oxidative phosphorylation and fatty acid metabolism. Research has shown that inhibiting PMI, the initial enzyme in the mannose metabolism pathway, enhances the sensitivity to both cytarabine and FLT3 inhibitors across various AML models. This PMI inhibition activates the ATF6 component of the unfolded protein response (UPR). Subsequently, this component impairs fatty acid metabolism, resulting in the intracellular accumulation of polyunsaturated fatty acids (PUFA), lipid peroxidation, and the induction of ferroptotic cell death in AML cells (Woodley et al., 2023). These findings underscore the significance of metabolic reprogramming in AML treatment and the potential benefits of combining PMI inhibition with mannose supplementation in leukemia therapy.

Pyroptosis, a recently identified form of regulated cell death, is characterized by perforations in the cell membrane. It is executed by members of the gasdermin family, including GSDMA, GSDMB, GSDMC, GSDMD, and GSDME (Kovacs and Miao, 2017). Notably, GSDME is predominantly expressed in the intestine and kidney, whereas its expression remains low in most tumor cells (Wang et al., 2017). Particularly during cancer chemotherapy, GSDME-mediated pyroptosis in tissue cells is linked to chemotherapy-induced side effects, intensifying patients’ distress and influencing the treatment trajectory (Shen et al., 2021; Xia et al., 2021). Ai et al. (2023) evidenced that mannose counteracts GSDME-mediated pyroptosis via AMPK activation, triggered by the metabolite N-acetylglucosamine-6-phosphate (GlcNAc-6P) (Ai et al., 2023). Intracellular entry of mannose elevates GlcNAc-6P levels via the HBP pathway. This metabolite subsequently binds to AMPK, promoting its phosphorylation by LKB1. The activated AMPK then phosphorylates the Thr6 site of GSDME, preventing caspase-3 binding and cleavage, thereby inhibiting pyroptosis. Beyond uncovering mannose’s novel mechanism in pyroptosis inhibition, this research also substantiates that mannose can mitigate intestinal toxic side effects caused by chemotherapeutic agents, such as cisplatin or oxaliplatin, both in mouse models and clinical patients with gastrointestinal cancers. Such insights breathe new life into an old drug, offering fresh perspectives and strategies for clinically alleviating chemotherapy’s side effects and holding promising therapeutic potential.

The effect of mannose on inflammatory diseases has been continuously discovered through extensive research on mannose. Urinary tract infections (UTIs) triggered by bacterial invasion of the urinary tract epithelium, which is most common in women, have a high recurrence rate, and their incidence increases significantly after menopause (Foxman and Brown, 2003). The ability of lectin molecules in the bacterial cell wall to bind to structures, such as mannose and fucose, on the surface of human cells is a significant factor in infection development. Escherichia coli, specifically Uropathogenic E. coli (UPEC), is the primary causative agent of symptomatic UTIs, contributing to approximately 80% of all UTIs. The type I bacterial pilus adhesin protein, FimH, found in UPEC binds to mannose structures on urinary tract epithelial cells. This binding facilitates bacterial adhesion and elicits an inflammatory response (Hatton et al., 2020; Krogfelt et al., 1990). Antibiotics are the first line of defense in the treatment of UTIs. However, the escalating challenge of antibiotic resistance underscores the imperative need for non-antibiotic alternatives in UTI prevention and treatment. Numerous studies have validated the substantial benefits of mannose in alleviating urinary tract infections and enhancing patients’ quality of life. The mechanism is that mannose inhibits bacterial adhesion to the urinary epithelium and simulates the barrier function of the uroepithelium, thereby effectively inhibiting UTIs. Bacteria bound to free D-mannose in the urine, as opposed to proteins on the surface of vascular cells, are expelled from the body via the urine stream (Kranjčec et al., 2013; Domenici et al., 2016; Cooper et al., 2022). Lenger et al. (2020) reported that mannose doses ranging from 420 mg to 2 g, administered 1 to 3 times daily over intervals of one week per month, were generally well tolerated. Side effects were minimal, with diarrhea reported by a small percentage of participants, and there was evidence of protection against recurrent UTIs (Lenger et al., 2020). In a separate study, Kyriakides et al. (2021) found that dosages of mannose between 500 mg to 2 g, given over varying durations (from 3 days up to 6 months), not only reduced the incidence of recurrent UTIs but also extended the intervals between successive infections, improving overall patient well-being (Kyriakides et al., 2021). Ongoing and optimized clinical trials continue to focus on the potential of mannose in UTI prevention and treatment (Konesan et al., 2022). Radulescu et al. (2020) highlighted that a combined treatment of cranberry extract and D-mannose might bolster the sensitivity of uropathogens to antibiotics during acute UTI treatment (Radulescu et al., 2020). Moreover, post-cystoscopy administration of D-mannose and Saccharomyces boulardii was found to markedly decrease UTI incidence, mitigate the severity of lower urinary tract symptoms (LUTS), and reduce localized discomfort (Quattrone et al., 2023). Lenger et al. (2023) further investigated the combined efficacy of mannose with vaginal estrogen therapy (VET) in preventing recurrent UTIs (Lenger et al., 2023).

Osteoarthritis (OA) is a complex disease characterized by cartilage degeneration, bone redundancy formation, joint inflammation, and subchondral bone remodeling, which has been challenging to treat because of its heterogeneity. IL-1β promotes matrix-degrading enzyme activity and apoptosis in chondrocytes, thereby accelerating the cartilage degeneration associated with osteoarthritis. Mannose has a protective effect on the cartilage in OA. D-mannose may induce autophagy in IL-1β-treated rat chondrocytes by promoting AMPK phosphorylation, inhibiting OA degeneration. In vivo experiments confirmed that a median dose of D-mannose inhibited monosodium iodoacetate (MIA)-induced OA development (Lin et al., 2021). Conversely, chondrocyte ferroptosis is implicated in the progression of OA. D-mannose can mitigate OA progression by suppressing HIF-2α-mediated sensitization of chondrocytes to ferroptosis. These findings hint at mannose’s potential as a therapeutic strategy for diseases linked to Ferroptosis (Zhou et al., 2021).

Mannose is linked to atopic dermatitis (AD), a chronic inflammatory disease with recurrent pruritus. In a mouse model of AD induced by DNCB (2,4-dinitrochlorobenzene), D-mannose substantially reduced skin damage and restored skin barrier function (Luo et al., 2022). D-mannose inhibited the TNF-α-induced increase in inflammatory cytokine expression and substantially downregulated the TNF-α-induced activation of the mTOR/NF-κB signaling pathway. This finding is the first indication that D-mannose plays a role in local skin inflammation, suggesting its potential use in treating AD (Luo et al., 2022). Psoriasis is a chronic autoimmune inflammatory skin condition with a yet-to-be-determined pathogenesis, posing significant treatment challenges. This condition places a significant physical and psychological toll on those afflicted. The pathogenesis of psoriatic inflammation involves a complex, self-perpetuating cycle driven by keratinocytes (KC) and various immune cells (Armstrong and Read, 2020). Recent findings have suggested that mannose can modulate this cycle. Specifically, mannose suppresses the expression of HIF-1α and diminishes the expression level of the chemokine CCL20 in keratinocytes. This activity, in turn, hampers the local recruitment of Th17 cells, disrupting the KC-Th17 cell feedback loop and consequently reducing the cutaneous inflammation characteristic of psoriasis in mouse models (Jiang et al., 2023).

Inflammatory bowel disease (IBD) is a chronic inflammatory condition with a rising incidence worldwide. It encompasses conditions such as Crohn’s disease (CD) and ulcerative colitis (UC). IBD is primarily characterized by immune response dysregulation, aberrant cytokine secretion, intestinal flora dysbiosis, and compromised barrier function (Maloy and Powrie, 2011). It is reported that patients with IBD and mice with experimental colitis had elevated mannose levels. In IL-10-deficient mice, mannose ameliorated the intestinal barrier damage caused by DSS-induced and spontaneous colitis. In the context of intestinal epithelial damage, mannose improved lysosomal integrity and limited the release of histone B, thereby preventing mitochondrial dysfunction and myosin light chain kinase (MLCK)-induced disruption of tight junctions. Mannose and mesalazine have a synergistic therapeutic effect on murine colitis (Dong et al., 2022). IBD is a multifaceted condition with a complex etiology involving susceptibility genes, immune system dynamics, environmental influences, and gut microbiota interactions (Ramos and Papadakis, 2019). At its core, IBD pathogenesis hinges on intricate epithelial-immune interactions. A compromised intestinal epithelial function allows gut microbes to infiltrate the lamina propria, activating intestinal immune cells. This cascade produces an influx of inflammatory cytokines, further damaging intestinal epithelial cells (IECs). Notably, excessive endoplasmic reticulum stress (ERS)—a distinctive feature of IBD pathogenesis—results in IEC apoptosis, further compromising epithelial integrity (Eugene et al., 2020). Xiao et al. (2023a) unveiled a novel pathway wherein mannose metabolism mitigates colitis development and aids in its recovery (Xiao et al., 2023a). In this context, macrophages release the inflammatory cytokine TNF-α, exacerbating pathological ERS in IECs. Mannose plays a dual protective role. First, mannose counteracts this stress by ensuring consistent protein N-glycosylation, curtailing inflammatory responses in colonic macrophages and preserving epithelial cell integrity. Second, mannose curbs TNF-α mRNA translation by reducing 3-phosphoglyceraldehyde levels in macrophages, subsequently fostering GAPDH’s binding affinity to TNF-α mRNA. Therefore, mannose metabolism effectively disrupts the detrimental interplay between TNF-α-afflicted IECs and intestinal macrophages, rectifying the perturbed immune metabolism within the gastrointestinal tract. Further insights reveal marked disparities in mannose metabolism-associated enzymes in the intestinal mucosa of IBD patients compared with those of healthy individuals, indicating dysregulation of mannose metabolism in IBD-afflicted colonic mucosa. Specifically, PMM2 and PMI emerge as pivotal mannose-metabolizing enzymes. A deep dive into single-cell sequencing datasets unveiled that IECs specifically upregulate PMM2 to alleviate ERS, whereas colon macrophages predominantly downregulate PMI. This differential expression implies that as IECs necessitate elevated PMM2 expression to counteract ERS, lamina propria’s immune cells, such as macrophages, demand glycolysis down-regulation to temper their inflammatory response. In sum, these revelations underscore the closely-knit anti-ERS and anti-inflammatory attributes of mannose, which collectively fortify the intestinal barrier against colitis.

Not only does D-mannose play a role in the treatment of tumors and inflammatory diseases, but it has also been reported to suppress Plasmodium infection by modulating multiple host immune pathways. Plasmodium berghei-infected mice fed D-mannose experienced weight loss and a reduction in parasitemia without significant side effects, a mechanism that is independent of cellular oxidative stress. Mannose increases the accumulation of splenic macrophages in P. berghei-infected C57BL/6 mice. Mannose reduced the incidence of experimental cerebral malaria (ECM) in a rodent disease model. Mannose treatment of P. berghei-infected mice decreased the expression of the T-cell activation marker CD69 in peripheral blood and brain, the expression of mRNA levels of the inflammatory factors IFN-γ and TNF-α, and the expression of CXCR3, which prevented the migration of activated T cells to the brain. These findings suggest that mannose could be used as a potential malaria treatment aid (Lv et al., 2022).